Our findings highlight GATC as a promising therapeutic candidate for MASLD, demonstrating significant lipid-clearing, antioxidant, and anti-inflammatory activities at concentrations of 5 μM and 10 μM. This evidence concerns the gene GATC and metabolic dysfunction-associated steatotic liver disease.